The 36-month beta value for SCYX is at 1.63. Analysts have varying views on the stock, with 2 analysts rating it as a “buy”, 1 rating it as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for SCYX is 37.16M, and currently, shorts hold a 1.68% of that float. The average trading volume for SCYX on July 04, 2025 was 140.95K shares.
SCYX stock’s latest price update
Scynexis Inc (NASDAQ: SCYX)’s stock price has increased by 1.57% compared to its previous closing price of $0.72. However, the company has seen a -0.69% decrease in its stock price over the last five trading sessions. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC bought a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 43,859 shares of the company’s stock, valued at approximately $53,000. Squarepoint Ops LLC owned approximately 0.12% of SCYNEXIS as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors and hedge funds have also bought and sold shares of SCYX. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in SCYNEXIS by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 195,393 shares of the company’s stock worth $236,000 after buying an additional 35,233 shares during the last quarter. Millennium Management LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $31,000. Jane Street Group LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $32,000. Northern Trust Corp grew its position in SCYNEXIS by 51.9% during the fourth quarter. Northern Trust Corp now owns 153,518 shares of the company’s stock worth $186,000 after buying an additional 52,466 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $25,000. Institutional investors own 54.37% of the company’s stock. Analysts Set New Price Targets Separately, Wall Street Zen started coverage on SCYNEXIS in a research report on Friday, May 16th. They set a “sell” rating on the stock. View Our Latest Analysis on SCYX SCYNEXIS Stock Performance Shares of SCYX stock opened at $0.88 on Wednesday. The stock’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $1.03. The company has a market cap of $34.42 million, a PE ratio of -1.19 and a beta of 1.65. SCYNEXIS, Inc. has a fifty-two week low of $0.72 and a fifty-two week high of $2.29. SCYNEXIS (NASDAQ:SCYX – Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.14 million. About SCYNEXIS (Free Report) SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
SCYX’s Market Performance
SCYX’s stock has fallen by -0.69% in the past week, with a monthly drop of -17.24% and a quarterly drop of -23.01%. The volatility ratio for the week is 6.39% while the volatility levels for the last 30 days are 6.74% for Scynexis Inc The simple moving average for the last 20 days is -5.92% for SCYX stock, with a simple moving average of -33.96% for the last 200 days.
Analysts’ Opinion of SCYX
Many brokerage firms have already submitted their reports for SCYX stocks, with Guggenheim repeating the rating for SCYX by listing it as a “Buy”. The predicted price for SCYX in the upcoming period, according to Guggenheim is $25 based on the research report published on January 22, 2021 of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see SCYX reach a price target of $30. The rating they have provided for SCYX stocks is “Overweight” according to the report published on January 06th, 2021.
Maxim Group gave a rating of “Buy” to SCYX, setting the target price at $6 in the report published on June 27th of the previous year.
SCYX Trading at -15.11% from the 50-Day Moving Average
After a stumble in the market that brought SCYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.06% of loss for the given period.
Volatility was left at 6.74%, however, over the last 30 days, the volatility rate increased by 6.39%, as shares sank -22.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.55% lower at present.
During the last 5 trading sessions, SCYX fell by -0.69%, which changed the moving average for the period of 200-days by -49.90% in comparison to the 20-day moving average, which settled at $0.7772. In addition, Scynexis Inc saw -62.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Federated Hermes Kaufmann Smal, the 10% Owner of Scynexis Inc, proposed sale 128,957 shares at $1.23 during a trade that took place back on Dec 18 ’24, which means that Federated Hermes Kaufmann Smal is holding N/A shares at $158,617 based on the most recent closing price.
Stock Fundamentals for SCYX
Current profitability levels for the company are sitting at:
- -15.26% for the present operating margin
- 1.0% for the gross margin
The net margin for Scynexis Inc stands at -11.42%. The total capital return value is set at -0.61%. Equity return is now at value -43.47%, with -29.10% for asset returns.
Based on Scynexis Inc (SCYX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -11.04. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -28.79.
Currently, EBITDA for the company is -18.58 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 10.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.83.
Conclusion
In conclusion, Scynexis Inc (SCYX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
